Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spine-Tech spinal implant IDE rejection Aug. 1 reaffirms two-year data rule, company says.

This article was originally published in The Gray Sheet

Executive Summary

SPINE-TECH IDE REJECTION AUG. 1 REAFFIRMS TWO-YEAR FOLLOW-UP REQUIREMENT for spinal implant studies, the company maintains in an Aug. 20 citizen's petition to FDA. The spinal implant maker says that its investigational device exemption application for a "new spinal device" was denied by FDA on Aug. 1 because "the protocol did not require two-year follow-up data on all patients in the trial" (emphasis Spine-Tech's). Spine-Tech urges FDA to reject a premarket approval application for Sofamor Danek's Novus LC threaded interbody fusion system due to alleged lack of follow-up data.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT008732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel